IMO-2055

DRUG3 trials

Sponsors

EMD Serono, Idera Pharmaceuticals, Inc.

Conditions

Colorectal CancerNon-Small Cell Lung CancerRenal Cell Carcinoma

Phase 1

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

CompletedNCT00633529

EMD SeronoNon-Small Cell Lung Cancer

Start: 2007-11-30End: 2011-03-31Updated: 2013-10-22

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

TerminatedNCT00719199

EMD SeronoColorectal Cancer

Start: 2009-01-31End: 2011-08-31Updated: 2013-10-22

Phase 2

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

CompletedNCT00729053

Idera Pharmaceuticals, Inc.Renal Cell Carcinoma

Start: 2004-06-30End: 2008-11-30Updated: 2018-06-12

Related Papers

Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.

2015-01-2818 citations